Navigation Links
Isis Earns $3 Million Payment as Collaboration With GSK Expands
Date:5/16/2011

CARLSBAD, Calif., May 16, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $3 million payment from GlaxoSmithKline (NYSE: GSK) related to the initiation of a sixth program under its collaboration to discover and develop drugs to treat rare and infectious diseases. This expansion follows the identification of the first development candidate from the collaboration in July of last year.

"We are pleased to announce this latest development in our alliance with GSK.  In just over a year into this alliance, we have identified our first development candidate, ISIS-TTRRx, which is ready to begin a Phase 1 clinical study. We look forward to achieving further success in the collaboration. Additionally, we recently received recognition from our industry peers for this collaboration by receiving the Breakthrough Alliance Award of 2011 sponsored by Deloitte Recap," said B. Lynne Parshall, Chief Operating Officer and CFO of Isis.  "We and GSK are committed to working together to apply antisense technology to develop new treatments for rare and severe diseases.  We benefit from GSK's expertise as we move these programs forward."

Isis entered into a strategic alliance with GSK in March 2010 to develop RNA therapeutics.  With the latest $3 million payment, Isis has earned $38 million in upfront payments from GSK.  Under the terms of the agreement, Isis is eligible to receive license fees and milestone payments, totaling nearly $1.5 billion, in the event all six programs are successfully developed for one or more indications and commercialized through to pre-agreed sales targets.  Isis is eligible to receive on average up to $20 million in milestone payments per program up to Phase 2 proof-of-concept.  GSK will have the option to license compounds at proof-of-concept and will be responsible for all further development and commercialization.  In addition, Isis will receive up to double-digit royalties on sales from any product that is successfully commercialized.  The alliance applies Isis' antisense drug discovery platform to discover and develop new therapeutics against targets for rare and serious diseases, including infectious diseases and some conditions causing blindness.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs and technology.  Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding Isis' collaboration with GlaxoSmithKline and Isis' research and development opportunities in disease areas including rare and infectious diseases.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2010 and its most recent quarterly on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc., its jointly owned subsidiary.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics is a trademark of Regulus Therapeutics Inc.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Joint HHC/GHX Project Earns Honors in Supply & Demand Chain Executives 2011 Executive 100
2. Allied Healthcare Earns Modest Profit in Tight Market
3. Kanzius Cancer Research Foundation Earns $1 for Each New Facebook Fan
4. Alere Earns NCQA Health Information Products Certification for Health Information Line
5. LearnSomething Releases REMS Training Program for Abstral
6. The Center for Radiation Therapy of Beverly Hills Earns ACR-ASTRO Accreditation
7. Joyant-Licensed Technology Earns Broad Patent Protection
8. Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration
9. IEHP Earns Highest Rating for Medicare Part D Quality and Performance
10. Medcos 2011 National Medicare Prescription Drug Plan (PDP) Earns CMS 5-Star Quality and Performance Rating
11. LearnSomething, Inc. Announces New Relationship With ASHP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 The key ... population, increasing diabetic population, accelerating economic growth and increasing healthcare ... industry are higher life expectancy of ESRD patients, rising demand ... markets. However, the expansion of the market is hindered by ... ...
(Date:3/23/2017)... , March 23, 2017  Transportation Insight, a ... an end-to-end supply chain management firm with expertise serving ... Product Solutions Rick Zaffarano was named a ... the Supply Chain by the only publication exclusively dedicated ... food supply chain. "Rick has brought to ...
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017  Eli ... the William Sansum Diabetes Center have established a research ... by diabetes through enhanced research, education and care. ... disease bears a disproportionate weight on Latino families in ... David Kerr , M.D., FRCPE, director of Innovation and ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 2017 , ... “End Time GPS”: a dauntless and enlightened study of ... GPS” is the creation of published author, Wesley Gerboth, a World War II veteran, ... space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon him ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Adventures of Joey, The Dog Who ... who lives his life to the fullest, as God intended. “The Adventures of Joey, ... a mother and grandmother pursuing her passion for writing, especially about truth and human ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic ... greater Houston Area. The new location is located at 2255 E. Mossy Oaks Rd., ... Village. This newest location will provide patients living in the north Houston area (The ...
(Date:3/23/2017)... Montclair, NJ (PRWEB) , ... March 23, 2017 ... ... the Renaissance Oklahoma City Convention Center at 10 North Broadway Avenue, will be ... 6.0 hours of relevant, practical instruction in the management of chronic pain. , ...
(Date:3/23/2017)... , ... March 23, 2017 , ... 82% of adults are unaware of the dangers ... not brush their teeth the minimum two times a day that dentists recommend. The ramifications ... 51 million hours of school and adults missing 164 million hours of work each year ...
Breaking Medicine News(10 mins):